Reused drugs such as disulfiram (DSF) and hydrogen sulphide (H2S) are also being investigated for their potential to increase FXR activity and improve lipid metabolism in MASLD/MASH patients [238,239]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.